(Re)Introducing Image Wisely.

Autor: Gingold E; Eric Gingold, PhD, FAAPM, FACR, is co-chair of the Image Wisely Executive Committee., Culp M; Melissa Culp, MEd, R.T.(R)(MR), is executive vice president of member engagement at the American Society of Radiologic Technologists.

Publikováno v: Radiologic technology [Radiol Technol] 2024 Jul; Vol. 95 (6), pp. 469-471.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Developing a Hybrid Radiologic-Pathologic Concordance Conference in a Major Nigerian Hospital: A Pilot Study.

Autor: Femi-Abodunde A; Department of Radiology, University of North Carolina, Chapel Hill, North Carolina. Electronic address: abiola.femiabod@gmail.com., Uvie-Emegbo YK; Department of Pathology, Lagos State University Teaching Hospital, Lagos, Nigeria., Adeyemi K; Department of Radiology, Lagos State University Teaching Hospital, Lagos, Nigeria., Culp M; Department of Radiology, University of North Carolina, Chapel Hill, North Carolina., Akinola A; Department of Radiology, Lagos State University Teaching Hospital, Lagos, Nigeria., Kuzmiak C; Vice Chair of Operations and Patient Safety and Director of the Breast Imaging Fellowship Program, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina., Omofoye TS; Strategic Director of Education, Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Journal of the American College of Radiology : JACR [J Am Coll Radiol] 2023 Feb; Vol. 20 (2), pp. 222-226. Date of Electronic Publication: 2022 Oct 23.

Intra-plaque Hemorrhage And Lipid-rich Necrotic Core May Be Objectively Quantified Using Histopathologic Correlates Automatically From CTA

Autor: Buckler, A., Sakamoto, A., St. Pierre, S., Culp, M., Johnson, K., Zhu, G., Virmani, R.

Publikováno v: In Journal of Cardiovascular Computed Tomography July-August 2021 15(4) Supplement:S45-S46

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.

Autor: Burns DK; Zinfandel Pharmaceuticals, Durham, NC, USA. Electronic address: dburns@zinfandelpharma.com., Alexander RC; Takeda Development Center Americas, Cambridge, MA, USA., Welsh-Bohmer KA; Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC, USA., Culp M; Takeda Development Center Americas, Cambridge, MA, USA., Chiang C; Zinfandel Pharmaceuticals, Durham, NC, USA., O'Neil J; Takeda Development Center Americas, Deerfield, IL, USA., Evans RM; Takeda Development Center Americas, Cambridge, MA, USA., Harrigan P; Takeda Development Center Americas, Deerfield, IL, USA., Plassman BL; Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC, USA., Burke JR; Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC, USA; Department of Neurology, Duke University Medical Center, Durham, NC, USA., Wu J; Takeda Development Center Americas, Cambridge, MA, USA., Lutz MW; Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC, USA; Department of Neurology, Duke University Medical Center, Durham, NC, USA., Haneline S; Zinfandel Pharmaceuticals, Durham, NC, USA., Schwarz AJ; Takeda Development Center Americas, Cambridge, MA, USA., Schneider LS; Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA., Yaffe K; University of California at San Francisco, San Francisco, CA, USA., Saunders AM; Zinfandel Pharmaceuticals, Durham, NC, USA., Ratti E; Takeda Development Center Americas, Cambridge, MA, USA.

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2021 Jul; Vol. 20 (7), pp. 537-547.